07:00 , Oct 1, 2007 |  BioCentury  |  Finance

3Q approvals

3Q approvals 3Q approvals Selected third quarter product approvals Company Approval Acambis (LSE:ACM) FDA approves ACAM2000 smallpox vaccine for use in subjects at high risk of exposure Anesiva (ANSV) FDA approves Zingo needle-free injection of...
07:00 , Sep 17, 2007 |  BC Week In Review  |  Clinical News

INNO 101 hepatitis C: Discontinued development

INNX discontinued development of HCV E1 vaccine after the compound missed the primary endpoint of a significant reduction in liver tissue damage vs. placebo in a Phase IIb trial (Study 918) in 122 patients. In...
07:00 , Jun 6, 2005 |  BC Week In Review  |  Clinical News

Hepatitis C: Phase IIb data

In the Phase IIb (study 916) trial in patients with chronic HCV infection, HCV E1 vaccine missed the primary endpoint of percent of patients with at least a 1-point improvement in liver fibrosis vs. placebo....
07:00 , Apr 4, 2005 |  BioCentury  |  Finance

2Q milestones

2Q milestones Selected milestones in the second quarter of 2005. Company Product Indication Milestones Amylin (AMLN)/Eli Lilly (LLY) Exenatide Type II diabetes PDUFA date 4/30 Antigenics (AGEN) Oncophage Renal cancer Ph III data Ardana (LSE:ARA)...
07:00 , Apr 7, 2003 |  BioCentury  |  Tools & Techniques

HCV pipeline

HCV pipeline Company Product Status Description Amarillo IFN alpha Ph II Oral formulation Anadys ANA245 Ph I Nucleoside with IFN alpha-like activity BioMedicines Omega interferon Ph II IFN omega Boehringer BILN 2061 Ph I Protease...
07:00 , Apr 7, 2003 |  BioCentury  |  Tools & Techniques

HCV clinical results

HCV clinical results Company Product Phase Patients Treatment Virologic response Biologic response BioMedicines Omega interferon Ph II 90 IFN omega 59% (33/56) of evaluable patients had undetectable HCV RNA N/A Innogenetics HCV E1 vaccine Ph...
07:00 , Oct 21, 2002 |  BC Week In Review  |  Clinical News

Hepatitis C: Phase II

Preliminary results of an open-label, 34-patient extension study of a placebo-controlled Belgian Phase II trial showed 38% (9/24) of patients who had received the vaccine during both the trial and the extension showed histological improvement....
07:00 , Jun 10, 2002 |  BC Week In Review  |  Clinical News

Hepatitis C: Phase IIa data

Forty-eight week results from a previously reported placebo-controlled Belgian Phase II study in 35 patients showed the vaccine was well tolerated and that E1-specific antibodies increased with each injection (see BioCentury, Dec. 24, 2001). Also,...
07:00 , Jun 10, 2002 |  BC Week In Review  |  Clinical News

Hepatitis C: INNX started an open-label extension of a Phase II study in 34 of the 35 patients enrolled in the original study. The protocol calls for 6 E1 vacci

Innogenetics N.V. (EASD:INNX), Ghent, Belgium   Product: Hepatitis C (HCV) E1 vaccine   Business: Infectious diseases   Therapeutic category: Viral infection   Target: Immune cells   Description: Efficacy as assessed by liver histology   Indication:...
08:00 , Dec 24, 2001 |  BC Week In Review  |  Clinical News

Hepatitis C: Phase IIa

INNX said that 28-week interim results from a placebo-controlled Phase IIa trial in Belgium in 35 patients with HCV showed that the vaccine is well tolerated and that antibody and T cell responses to E1...